{"doi":"10.1007/s41999-022-00627-3","title":"Sarcopenia reduces quality of life in the long-term: longitudinal analyses from the English longitudinal study of ageing","abstract":"PURPOSE: Mixed findings exist for sarcopenia/quality of life (QoL) relationship. Moreover, the majority of studies in this area have utilized a cross-sectional design or specific clinical populations. Therefore, the aim of the present study was to examine the association between sarcopenia at baseline and QoL at 10 years follow-up in a large representative sample of older English adults. METHODS: Sarcopenia was diagnosed as having low handgrip strength and low skeletal muscle mass index. QoL was measured using the CASP (control, autonomy, self-realisation and pleasure)-19, with higher values reflecting higher QoL. Multivariable logistic regression analysis was conducted to assess prospective associations between sarcopenia at baseline and poor QoL at follow-up; generalized linear model with repeated measures was used for reporting mean changes during follow-up between sarcopenia and not. RESULTS: Among 4044 older participants initially included at baseline (mean age: 70.7 years; 55.1% females), 376 had sarcopenia. In the multivariable analysis, after adjusting for several potential confounders, sarcopenia at baseline was associated with a higher incidence of poor QoL (odds ratio, OR = 5.82; 95% confidence interval, CI 3.45-9.82). After matching for QoL values at baseline and adjusting for potential confounders, people with sarcopenia reported significantly lower values in CASP-19 (mean difference = - 3.94; 95% CI - 4.77 to - 3.10). CONCLUSIONS: In this large representative sample of older English adults, it was observed that sarcopenia at baseline was associated with worse scores of QoL at follow-up compared to those without sarcopenia at baseline. It may be prudent to target those with sarcopenia to improve QoL.","journal":"European Geriatric Medicine","year":2022,"id":235564,"datarank":0.6554171778700533,"base_score":4.3694478524670215,"endowment":4.3694478524670215,"self_citation_contribution":0.6554171778700533,"citation_network_contribution":0.0,"self_endowment_contribution":0.6554171778700533,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":78,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9556,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2022-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":105393,"name":"Ai Koyanagi","orcid":"0000-0002-9565-5004","position":1,"is_corresponding":false},{"id":854311,"name":"Emanuele Cereda","orcid":"0000-0002-0747-1951","position":2,"is_corresponding":false},{"id":230304,"name":"Stefania Maggi","orcid":"0000-0002-0453-8663","position":3,"is_corresponding":false},{"id":620314,"name":"Mario Barbagallo","orcid":"0000-0002-1349-6530","position":4,"is_corresponding":false},{"id":674867,"name":"Ligia J. Domínguez","orcid":"0000-0003-1466-8610","position":5,"is_corresponding":false},{"id":681,"name":"Lee Smith","orcid":"0000-0002-5340-9833","position":6,"is_corresponding":false},{"id":687,"name":"Nicola Veronese","orcid":"0000-0002-9328-289X","position":0,"is_corresponding":true}],"reference_count":35,"raw_metadata":{"citation_network_status":"fetched"},"created_at":"2026-07-19T00:21:53.333008Z","pmid":"35212911","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}